Circio Holding ASA

📍 Oslo, Norway🗓 Founded 2010👥 37 employees💰 Last funded Aug 2014
Biotechnology Research🌐 circio.com
Website LinkedIn
Circio Holding ASA is a clinical stage company developing immune activators to target difficult-to-treat diseases. The company’s mission is to deploy vector-based technology to create a novel class of targeted, multi-functional circRNA medicines. It has established a cutting-edge circular RNA (circRNA) program and is collaborating with Prof Michael Uhlin and a team at the Karolinska Institutet in Stockholm with the intent to develop next generation RNA therapeutics for various applications. The company also has a mutant RAS cancer vaccine program, with two collaborative clinical trials underway in the USA and Norway. It is currently looking at options for the financing of a phase 2 study for ONCOS-102, a genetically modified oncolytic adenovirus.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2010
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Norway
1
Frequently asked questions
Who invested in Circio Holding ASA?
Circio Holding ASA has 1 investors on record on gritt.io, 1 mid-stage.
When did Circio Holding ASA last raise funding?
The most recent investment in Circio Holding ASA recorded on gritt.io was in August 2014.
When was Circio Holding ASA founded?
Circio Holding ASA was founded in 2010.
What industry is Circio Holding ASA in?
Circio Holding ASA operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Circio Holding ASA based?
Circio Holding ASA is headquartered in Oslo, Norway.